Moreover, the 36-month beta value for VYNE is 1.61. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VYNE is 13.23M and currently, short sellers hold a 1.64% of that float. On May 22, 2025, VYNE’s average trading volume was 177.65K shares.
VYNE) stock’s latest price update
VYNE Therapeutics Inc (NASDAQ: VYNE)’s stock price has dropped by -13.04 in relation to previous closing price of 1.15. Nevertheless, the company has seen a loss of -20.63% in its stock price over the last five trading days. globenewswire.com reported 2025-05-08 that Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 Expected cash runway into 2H 2026 BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced financial results as of and for the quarter ended March 31, 2025, and provided a business update.
VYNE’s Market Performance
VYNE Therapeutics Inc (VYNE) has seen a -20.63% fall in stock performance for the week, with a -46.24% decline in the past month and a -62.96% plunge in the past quarter. The volatility ratio for the week is 8.79%, and the volatility levels for the past 30 days are at 8.58% for VYNE. The simple moving average for the past 20 days is -24.84% for VYNE’s stock, with a -54.72% simple moving average for the past 200 days.
Analysts’ Opinion of VYNE
Many brokerage firms have already submitted their reports for VYNE stocks, with BTIG Research repeating the rating for VYNE by listing it as a “Buy.” The predicted price for VYNE in the upcoming period, according to BTIG Research is $8 based on the research report published on November 18, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see VYNE reach a price target of $7. The rating they have provided for VYNE stocks is “Buy” according to the report published on December 06th, 2021.
VYNE Trading at -35.97% from the 50-Day Moving Average
After a stumble in the market that brought VYNE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.74% of loss for the given period.
Volatility was left at 8.58%, however, over the last 30 days, the volatility rate increased by 8.79%, as shares sank -45.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -46.81% lower at present.
During the last 5 trading sessions, VYNE fell by -20.63%, which changed the moving average for the period of 200-days by -44.44% in comparison to the 20-day moving average, which settled at $1.3305. In addition, VYNE Therapeutics Inc saw -70.15% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VYNE starting from LEPORE PATRICK G, who purchase 15,000 shares at the price of $2.92 back on Jan 15 ’25. After this action, LEPORE PATRICK G now owns 51,472 shares of VYNE Therapeutics Inc, valued at $43,800 using the latest closing price.
Stock Fundamentals for VYNE
Current profitability levels for the company are sitting at:
- -74.15 for the present operating margin
- 0.66 for the gross margin
The net margin for VYNE Therapeutics Inc stands at -69.73. The total capital return value is set at -1.02. Equity return is now at value -66.15, with -56.95 for asset returns.
Based on VYNE Therapeutics Inc (VYNE), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -594.46.
Currently, EBITDA for the company is -43.63 million with net debt to EBITDA at 0.64. When we switch over and look at the enterprise to sales, we see a ratio of -18.98. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.47.
Conclusion
To wrap up, the performance of VYNE Therapeutics Inc (VYNE) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
